Stay updated on Magrolimab in Hematological Malignancies Clinical Trial
Sign up to get notified when there's something new on the Magrolimab in Hematological Malignancies Clinical Trial page.

Latest updates to the Magrolimab in Hematological Malignancies Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.7%
- Check35 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.0%
- Check50 days agoChange DetectedThe latest update on January 17, 2025, includes the posting of results for various cohorts in a study involving magrolimab and azacitidine for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), highlighting new treatment protocols and participant eligibility criteria, while previous entries related to specific cohorts and treatment details have been removed.SummaryDifference100%
- Check57 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
- Check87 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to Magrolimab in Hematological Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab in Hematological Malignancies Clinical Trial page.